COVID-19
Conditions
Keywords
COVID-19, Azvudine, severity
Brief summary
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
Detailed description
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.
Interventions
DRUGAzvudine
Received antiviral treatment with azvudine
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The COVID-19 positive patients
Exclusion criteria
1. patients treated with both azvudine and monotamivir; 2. patients receiving other antiviral drugs such as nematavir/ritonavir; 3. age < 18 years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality of COVID-19 patients | Time from onset to death | All-cause mortality of COVID-19 patients |
Countries
China
Outcome results
None listed